TERTIARY STRUCTURE DATA |
Homo sapiens
|
complex with ovalicin |
1.80 Å |
1B59 |
1B59 |
1B59 |
1B59 |
1B59 |
1B59 |
Liu et al., 1998 |
complex with TNP-470 inhibitor |
1.60 Å |
1B6A |
1B6A |
1B6A |
1B6A |
1B6A |
1B6A |
Liu et al., 1998 |
mature peptidase |
1.80 Å |
1BN5 |
1BN5 |
1BN5 |
1BN5 |
1BN5 |
1BN5 |
Liu et al., 1998 |
complex with fumagillin inhibitor |
1.80 Å |
1BOA |
1BOA |
1BOA |
1BOA |
1BOA |
1BOA |
Liu et al., 1998 |
mature peptidase |
2.00 Å |
1KQ0 |
1KQ0 |
1KQ0 |
1KQ0 |
1KQ0 |
1KQ0 |
Nonato et al., 2006 |
mature peptidase |
1.90 Å |
1KQ9 |
1KQ9 |
1KQ9 |
1KQ9 |
1KQ9 |
1KQ9 |
Nonato et al., 2006 |
mature peptidase |
1.60 Å |
1QZY |
1QZY |
1QZY |
1QZY |
1QZY |
1QZY |
Towbin et al., 2003 |
mature peptidase |
1.90 Å |
1R58 |
1R58 |
1R58 |
1R58 |
1R58 |
1R58 |
Sheppard et al., 2004 |
mature peptidase |
2.00 Å |
1R5G |
1R5G |
1R5G |
1R5G |
1R5G |
1R5G |
Sheppard et al., 2004 |
mature peptidase |
2.40 Å |
1R5H |
1R5H |
1R5H |
1R5H |
1R5H |
1R5H |
Sheppard et al., 2004 |
mature peptidase |
1.85 Å |
1YW7 |
1YW7 |
1YW7 |
1YW7 |
1YW7 |
1YW7 |
Sheppard et al., 2006 |
mature peptidase |
2.65 Å |
1YW8 |
1YW8 |
1YW8 |
1YW8 |
1YW8 |
1YW8 |
Sheppard et al., 2006 |
mature peptidase |
1.64 Å |
1YW9 |
1YW9 |
1YW9 |
1YW9 |
1YW9 |
1YW9 |
Sheppard et al., 2006 |
mature peptidase |
1.90 Å |
2ADU |
2ADU |
2ADU |
2ADU |
2ADU |
2ADU |
Kallander et al., 2005 |
mature peptidase |
2.50 Å |
2EA2 |
2EA2 |
2EA2 |
2EA2 |
2EA2 |
2EA2 |
Wang et al., 2007 |
mature peptidase |
2.35 Å |
2EA4 |
2EA4 |
2EA4 |
2EA4 |
2EA4 |
2EA4 |
Wang et al., 2007 |
mature peptidase |
1.95 Å |
2GA2 |
2GA2 |
2GA2 |
2GA2 |
2GA2 |
2GA2 |
Kawai et al., 2006 |
mature peptidase |
1.90 Å |
2OAZ |
2OAZ |
2OAZ |
2OAZ |
2OAZ |
2OAZ |
Marino et al., 2007 |
complex with spiroepoxytriazole inhibitor (+)-31a |
1.75 Å |
5CLS |
5CLS |
5CLS |
5CLS |
5CLS |
5CLS |
|
structure of human methionine aminopeptidase 2 with covalent spiroepoxytriazole inhibitor (-)-31b |
1.49 Å |
5D6E |
5D6E |
5D6E |
5D6E |
5D6E |
5D6E |
|
complex with spiroepoxytriazole inhibitor (+)-31b |
1.55 Å |
5D6F |
5D6F |
5D6F |
5D6F |
5D6F |
5D6F |
|
potent, reversible metap2 inhibitors via fragment based drug discovery |
1.60 Å |
5JFR |
5JFR |
5JFR |
5JFR |
5JFR |
5JFR |
|
potent, reversible metap2 inhibitors via fbdd |
1.80 Å |
5JHU |
5JHU |
5JHU |
5JHU |
5JHU |
5JHU |
|
potent, reversible metap2 inhibitors via fbdd |
2.15 Å |
5JI6 |
5JI6 |
5JI6 |
5JI6 |
5JI6 |
5JI6 |
|
complex with an inhibitor 6-((r)-2-o-tolyloxymethyl-pyrrolidin-1-yl)-9h- purine |
1.69 Å |
5LYW |
5LYW |
5LYW |
5LYW |
5LYW |
5LYW |
|
complex with an inhibitor 5-((r)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-isoquinoline |
1.90 Å |
5LYX |
5LYX |
5LYX |
5LYX |
5LYX |
5LYX |
|
complex with an inhibitor (s)-3-hydroxy-2-oxo-1-(2-oxo-1,2,3,4-tetrahydro- quinolin-6-yl)-pyrrolidine-3-carboxylic acid 3-chloro-5-fluoro- benzylamide |
1.80 Å |
6QED |
6QED |
6QED |
6QED |
6QED |
6QED |
|
complex withan inhibitor (s)-3-hydroxy-2-oxo-1-phenyl-pyrrolidine-3-carboxylic acid 3-chloro-5-fluoro-benzylamide |
1.79 Å |
6QEF |
6QEF |
6QEF |
6QEF |
6QEF |
6QEF |
|
complex withan inhibitor 2-oxo-1-phenyl-pyrrolidine-3-carboxylic acid (2- thiophen-2-yl-ethyl)-amide |
2.08 Å |
6QEG |
6QEG |
6QEG |
6QEG |
6QEG |
6QEG |
|
complex withan inhibitor 5-chloro-quinolin-8-ol |
2.17 Å |
6QEH |
6QEH |
6QEH |
6QEH |
6QEH |
6QEH |
|
complex withan inhibitor 5,6-difluoro-3-(2-isopropoxy-4-piperazin-1-yl-phenyl)- 1h-indole-2-carboxylic acid amide |
1.80 Å |
6QEI |
6QEI |
6QEI |
6QEI |
6QEI |
6QEI |
|
complex withan inhibitor thiophene-2-sulfonic acid (4-fluoro-benzyl)-(4h-[1,2, 4]triazol-3-ylmethyl)-amide |
1.62 Å |
6QEJ |
6QEJ |
6QEJ |
6QEJ |
6QEJ |
6QEJ |
|